Striking phenotypic variation in a family with the P506S UBQLN2 mutation including amyotrophic lateral sclerosis, spastic paraplegia, and frontotemporal dementia.


Journal

Neurobiology of aging
ISSN: 1558-1497
Titre abrégé: Neurobiol Aging
Pays: United States
ID NLM: 8100437

Informations de publication

Date de publication:
01 2019
Historique:
received: 08 02 2018
revised: 07 08 2018
accepted: 15 08 2018
pubmed: 24 10 2018
medline: 20 12 2019
entrez: 24 10 2018
Statut: ppublish

Résumé

Analysis of 226 exome-sequenced UK cases of familial amyotrophic lateral sclerosis (ALS) and frontotemporal dementia identified 2 individuals who harbored a P497H and P506S UBQLN2 mutation, respectively (n = 0.9%). The P506S index case presented with behavioral variant frontotemporal dementia at the age of 54 years then progressed to ALS surviving 3 years. Three sons presented with (1) slowly progressive pure spastic paraplegia with an onset at 25 years and (2) ALS with disease onset of 25 years and survival of 2 years, and (3) ALS presenting symptoms at the age of 26 years, respectively. Analysis of postmortem tissue from the index case revealed frequent neuronal cytoplasmic UBQLN2-positive inclusions in the dentate gyrus and TDP-43-positive neuronal cytoplasmic inclusions in the frontal and temporal cortex and granular cell layer of the dentate gyrus of the hippocampus. Furthermore, a comprehensive analysis of published UBQLN2 mutations demonstrated that only proline-rich domain mutations contribute to a significantly earlier age of onset in male patients (p = 0.0026).

Identifiants

pubmed: 30348461
pii: S0197-4580(18)30303-8
doi: 10.1016/j.neurobiolaging.2018.08.015
pii:
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
Autophagy-Related Proteins 0
Cell Cycle Proteins 0
DNA-Binding Proteins 0
TARDBP protein, human 0
UBQLN2 protein, human 0
Ubiquitins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

229.e5-229.e9

Subventions

Organisme : Medical Research Council
ID : MR/L021803/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L016397/1
Pays : United Kingdom
Organisme : Motor Neurone Disease Association
ID : SHAW/APR15/933-794
Pays : United Kingdom
Organisme : MRF
ID : MRF_MRF-060-0003-RG-SMITH
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1100695
Pays : United Kingdom
Organisme : Motor Neurone Disease Association
ID : ALCHALABI-DOBSON/APR14/829-791
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_G1000733
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0500289
Pays : United Kingdom
Organisme : Motor Neurone Disease Association
ID : SHAW/NOV14/985-797
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L501529/1
Pays : United Kingdom
Organisme : Motor Neurone Disease Association
ID : SREEDHARAN/APR16/849-791
Pays : United Kingdom
Organisme : Motor Neurone Disease Association
ID : SMITH/APR16/847-791
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_17115
Pays : United Kingdom
Organisme : Motor Neurone Disease Association
ID : SMITH/OCT16/888-792
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R024804/1
Pays : United Kingdom
Organisme : Motor Neurone Disease Association
ID : SHAW/APR15/970-797
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0900688
Pays : United Kingdom

Informations de copyright

Copyright © 2018 Elsevier Inc. All rights reserved.

Auteurs

Soragia Athina Gkazi (SA)

United Kingdom Dementia Research Institute Centre, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Camberwell, London, UK.

Claire Troakes (C)

United Kingdom Dementia Research Institute Centre, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Camberwell, London, UK.

Simon Topp (S)

United Kingdom Dementia Research Institute Centre, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Camberwell, London, UK.

Jack W Miller (JW)

United Kingdom Dementia Research Institute Centre, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Camberwell, London, UK.

Caroline A Vance (CA)

United Kingdom Dementia Research Institute Centre, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Camberwell, London, UK.

Jemeen Sreedharan (J)

United Kingdom Dementia Research Institute Centre, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Camberwell, London, UK.

Ammar Al-Chalabi (A)

United Kingdom Dementia Research Institute Centre, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Camberwell, London, UK.

Janine Kirby (J)

Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.

Pamela J Shaw (PJ)

Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.

Safa Al-Sarraj (S)

United Kingdom Dementia Research Institute Centre, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Camberwell, London, UK.

Andrew King (A)

United Kingdom Dementia Research Institute Centre, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Camberwell, London, UK.

Bradley N Smith (BN)

United Kingdom Dementia Research Institute Centre, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Camberwell, London, UK.

Christopher E Shaw (CE)

United Kingdom Dementia Research Institute Centre, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Camberwell, London, UK. Electronic address: chris.shaw@kcl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH